An observational study in Age-Related Macular Degeneration and Diabetic Retinopathy, sponsored by Notal Vision Ltd.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-13.
Sponsored by Notal Vision Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Macular Degeneration by Notal Vision Ltd. — none open to participants now, 1 under way, none of them phase 3. Macular Degeneration · Notal Vision Ltd..
Among the 26 studies in Macular Degeneration by Notal Vision Ltd., this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 2 that started in 2017, is one of 25 observational ones, and was the 20th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
Browse Macular Degeneration studies →None of the 26 studies in Macular Degeneration by Notal Vision Ltd. is open now. The open studies under Macular Degeneration, anywhere →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2017.
This study's planned enrollment of 33 is below the median of 110 across 409 observational studies indexed under Macular Degeneration.
Median enrollment 1,520 across the 1 interventional studies, 42 across the 25 observational. Of the 23 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
Notal Vision Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Macular Degeneration by Notal Vision Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Comparison between retinal measurements, done by the Notal-OCT imaging and a commercial OCT (Optical Coherence Tomography)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Notal OCT
Device: Notal OCT
Device: Notal OCT
Device: Notal OCT
Imaging using Notal OCT
The level of agreement between NOTAL-OCT and commercial OCT in detecting fluid in the 10 central degrees of the macula.
OCT B-scans from both devices will be graded for fluid by an eye care professional and results per macula will be analyzed. A binary decision "there is fluid" or "there is no fluid" will be given to each macula (10 central degrees). Then agreement between decisions, commercial and Notal OCT, will be compared
Time frame: 1 year
No study locations are listed for this record.
Ran from Jan 2017 to primary completion in May 2018, 15 months.
Of 56 industry-sponsored observational studies under Macular Degeneration, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's 15 months is below that.
Counting every sponsor, half of 161 studies reached it within 45 months; a quarter within 16 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.